Literature DB >> 2431371

Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty.

V S Nirankari, J C Baer.   

Abstract

Corneal argon laser photocoagulation (CALP) was used in 13 patients to treat deep stromal vascular ingrowth. Eight patients had undergone successful penetrating keratoplasty but had developed deep stromal vessels into the graft associated with signs of graft rejection, which did not improve with steroid treatment alone (group 1). After CALP, there was marked regression of the neovascularization with reversal of graft rejection in all eyes. Three additional patients with vascularized corneas, referred for penetrating keratoplasty, underwent CALP preoperatively with obliteration of the vessels (group 2). Two of these patients have since undergone keratoplasty and, in both, the grafts have remained avascular and clear over a 21-month follow-up. Two other patients with corneal injury and progressive corneal opacification and vascularization have also been treated with CALP (group 3). CALP may be a useful adjunct in the treatment of corneal neovascularization. Further clinical studies are needed to define its exact role.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2431371     DOI: 10.1016/s0161-6420(86)33581-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  11 in total

1.  Laser photocoagulation for corneal stromal vascularization.

Authors:  V S Nirankari
Journal:  Trans Am Ophthalmol Soc       Date:  1992

Review 2.  Graft failure: II. Ocular surface complications.

Authors:  Samar A Al-Swailem
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

Review 3.  Management of high-risk corneal transplantation.

Authors:  Antonio Di Zazzo; Ahmad Kheirkhah; Tulio B Abud; Sunali Goyal; Reza Dana
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

Review 4.  Nanotechnology in corneal neovascularization therapy--a review.

Authors:  Lilian Gonzalez; Raymond J Loza; Kyu-Yeon Han; Suhair Sunoqrot; Christy Cunningham; Patryk Purta; James Drake; Sandeep Jain; Seungpyo Hong; Jin-Hong Chang
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-20       Impact factor: 2.671

Review 5.  Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).

Authors:  William Stevenson; Sheng-Fu Cheng; Mohammad H Dastjerdi; Giulio Ferrari; Reza Dana
Journal:  Ocul Surf       Date:  2012-01-25       Impact factor: 5.033

6.  Photothrombosis of corneal neovascularization by photodynamic therapy utilizing verteporfin and diode laser.

Authors:  Aziza Ahmed Hassan; Dina Foad Ghoneim; Amr Abdelraheem El-Dib; Salwa Abdelkawi Ahmed; Ahmed Medhat Abdel-Salam
Journal:  J Lasers Med Sci       Date:  2013

Review 7.  An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.

Authors:  Chenchen Zhang; Yuan Yin; Jing Zhao; Yanxia Li; Yuanping Wang; Zhaoying Zhang; Lingzhi Niu; Yajuan Zheng
Journal:  Int J Nanomedicine       Date:  2022-10-19

8.  Corneal neovascularization in rats as a model for photothrombotic therapy using bacteriochlorin a and an argon laser.

Authors:  C A van Gool; H J Schuitmaker; M J Jager
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-07       Impact factor: 3.117

9.  Attenuation of corneal neovascularization by topical low-molecular-weight heparin-taurocholate 7 without bleeding complication.

Authors:  Jae Yong Kim; Soo Yeon Kim; Mi Hyun Cheon; Eun-Soon Kim; In Seok Song; Myoung Joon Kim; Hungwon Tchah
Journal:  Int J Ophthalmol       Date:  2016-09-18       Impact factor: 1.779

10.  KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularization.

Authors:  Tao Li; Andina Hu; Shiqing Li; Yan Luo; Juan Huang; Honghua Yu; Wei Ma; Jianying Pan; Qi Zhong; Jin Yang; Jianming Wu; Shibo Tang
Journal:  Mol Vis       Date:  2011-03-25       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.